Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in Chinese adolescents with chronic graft-versus-host disease
2026-000401-14Phase 4
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Primary endpoint: Plasma concentrations of belumosudil at specified time points.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2026-000401-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000401-14.